Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab induction in Crohn's disease (MOTIVATE)
NCT03104413Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 43
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Dec 2017; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03104413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104413.